Correlation of Beta-2 Adrenergic Receptor Expression in Tumor-Free Surgical Margin and at the Invasive Front of Oral Squamous Cell Carcinoma

Denise Tostes Oliveira, Diego Mauricio Bravo-Calderón, Gustavo Amaral Lauand, Agnes Assao, José-Manuel Suárez-Peñaranda, Mario Pérez-Sayáns, Abel García-García, Aparecido Nilceu Marana, Suely Nonogaki, José Roberto Pereira Lauris, and Luiz Paulo Kowalski

1Department of Stomatology, Area of Pathology, Bauru School of Dentistry, University of São Paulo, 17012-901 Bauru, SP, Brazil
2Department of Pathology and Forensic Sciences, University Hospital and School of Medicine of Santiago de Compostela, Santiago de Compostela, 15706 Galicia, Spain
3Faculty of Medicine and Dentistry, Institute of Research of Santiago de Compostela (IDIS), Clinical Hospital University of Santiago, Santiago de Compostela, 15782 A Coruña, Spain
4Department of Computing, Faculty of Sciences, São Paulo State University (UNESP), 17033-360 Bauru, SP, Brazil
5Pathology Division, Adolfo Lutz Institute, 01246-902 São Paulo, SP, Brazil
6Department of Community Dentistry, Bauru School of Dentistry, University of São Paulo, 17012-901 Bauru, SP, Brazil
7Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, 01509-010 São Paulo, SP, Brazil

Correspondence should be addressed to Denise Tostes Oliveira; denisetostes@usp.br

Received 16 December 2015; Revised 1 February 2016; Accepted 10 February 2016

Academic Editor: Thomas R. Chauncey

Copyright © 2016 Denise Tostes Oliveira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The beta-2 adrenergic receptor is expressed by neoplastic cells and is correlated with a wide spectrum of tumor cell mechanisms including proliferation, apoptosis, angiogenesis, migration, and metastasis. Objectives. The present study aimed to analyze the expression of the beta-2 adrenergic receptor (β2-AR) in tumor-free surgical margins of oral squamous cell carcinomas (OSCC) and at the invasive front. Sixty-two patients diagnosed with OSCC, confirmed by biopsy, were selected for the study. The clinicopathological data and clinical follow-up were obtained from medical records and their association with β2-AR expression was verified by the chi-square test or Fischer’s exact test. To verify the correlation of β2-AR expression in tumor-free surgical margins and at the invasive front of OSCCs, Pearson’s correlation coefficient test was applied. Results. The expression of β2-AR presented a statistically significant correlation between the tumor-free surgical margins and the invasive front of OSCC (r = 0.383; p = 0.002). The immunohistochemical distribution of β2-AR at the invasive front of OSCC was also statistically significant associated with alcohol (p = 0.038), simultaneous alcohol and tobacco consumption (p = 0.010), and T stage (p = 0.014). Conclusions. The correlation of β2-AR expression in OSCC and tumor-free surgical margins suggests a role of this receptor in tumor progression and its expression in normal oral epithelium seems to be constitutive.

1. Background

Chronic stress dysregulates the hypothalamic-pituitary-adrenal axis, elevating the production of stress related hormones, epinephrine, and norepinephrine [1]. These catecholamines seem to enhance the expression of vascular endothelial growth factor (VEGF) and the matrix of metalloproteinases (MMPs) in malignant tumors, contributing to tumor progression [2]. It is known that β2-AR is a member of a large family of G-protein-coupled receptors and is responsible for transduction signals from catecholamine ligands [3, 4]. Once β2-AR binds to catecholamine ligands, it stimulates
a G-protein receptor, resulting in adenylyl cyclase activity and, subsequently, in the generation of intracellular cyclic AMP (cAMP) that activates protein kinase A (PKA), which modulates several cellular functions [5]. A growing number of scientific evidences have verified that β2-AR is expressed by malignant neoplastic cells and that, under chronic psychological stress, through catecholamine induced activation, it could regulate a wide spectrum of tumor cell mechanisms including proliferation, apoptosis, angiogenesis, migration, and metastases [1, 2, 6–25].

Particularly, investigations in oral cancer cell lines have demonstrated that β2-AR signaling upregulates interleukin-6 (IL-6) mRNA, a cytokine that is involved in angiogenesis and tumor progression process, increasing proliferation and invasion of the tumor [16, 18]. Furthermore, Shang et al. also reported that positive β2-AR immunoeexpression in oral cancer is significantly correlated with age, tumor size, clinical stage, and cervical lymph node metastasis in OSCC patients, suggesting a role of β2-AR in the metastasis of oral cancer [16]. In contrast, our group, in a retrospective clinical study, showed that patients with OSCC, who exhibited strong β2-AR expression by malignant epithelial cells, presented higher survival rates compared with weak/negative β2-AR expression [21].

Although β2-AR is present in normal oral tissues, the exact differences between β2-AR expression levels in normal oral epithelium and oral cancer are not so clear [3, 16, 18, 21]; for example, β2-AR was highly expressed in OSCC tissue when compared to adjacent normal oral mucosa [16]. In turn, Bernabé et al. showed no significant differences between β2-AR mRNA levels in normal oral mucosa and OSCC specimens [18].

In order to contribute with recent studies and investigate the role of β2-AR in OSCC, the present study aimed to analyze the expression of β2-AR in the tumor-free surgical margin and at the invasive front of a large sample of OSCC to verify if β2-AR expression is correlated with tumor-free surgical margins and the invasive front of OSCCs and to explore associations between β2-AR expression levels and clinicopathological features.

2. **Patients and Methods**

2.1. **Patients and Tumor Samples.** The present retrospective study was based on the analysis of 62 patients previously studied by Bravo-Calderón et al. [21]. All patients were submitted to surgical treatment for primary oral squamous cell carcinoma at the Head and Neck Surgery and Otorhinolaryngology Department of the A.C. Camargo Cancer Center, São Paulo, Brazil, from 1970 to 2000. The inclusion criteria were (i) primary OSCC located in the oral tongue, floor of the mouth, retromolar area or inferior gingiva confirmed by biopsy; (ii) patients submitted to surgery as the initial treatment followed or not by radiotherapy; (iii) clinical stages II, III, and IV; and (iv) tumor and morphologically normal/nondysplastic tumor-free surgical margin tissues available for microscopic analysis. Patients with other simultaneous primary tumors, or with distant metastases at the time of admission, undergoing preoperative chemother-apy and/or radiotherapy were not included. Clinical data of the patients were collected from the hospital records and included age, gender, ethnic group, tobacco and alcohol consumption, tumor location, and disease stage according to the TNM system of the International Union Against Cancer (UICC) [26], and treatment (surgery, postoperative adjuvant radiotherapy) and clinical follow-up (recurrence, cervical lymph node metastasis, distant metastasis, or occurrence of second primary tumor). The present study was approved by the Research Ethics Committee of the A.C. Camargo Cancer Center, São Paulo, Brazil (#1385/10).

A formalin-fixed 3 μm thick section of tumor tissue was selected and paraffin-embedded for hematoxylin and eosin staining and immunohistochemistry analysis of β2-AR. Three observers (Denise Tostes Oliveira, Gustavo Amaral Lauand, Diego Mauricio Bravo-Calderón) analyzed the tumor sections without knowledge of the clinical data. Histopathological malignancy grade of OSCC was determined according to the Bryne et al. system [27]. Tumor infiltration to adjacent structures, vascular embolization, and lymph node metastases (pN+) were also reported.

2.2. Beta-2 Adrenergic Receptor Expression in the Tumor-Free Surgical Margin of Oral Squamous Cell Carcinoma. Sections of the 62 OSCC specimens were deparaffinized in xylene and hydrated using graded alcohol/water baths. Antigen retrieval was performed using 10 mM citrate buffer (pH 6.0) in a domestic pressure cooker (Nigro, model Eterna 4.5 L, Araraquara, SP, Brazil) for 4 min, and then the endogenous peroxidase activity was blocked by incubation in 3% H2O2 for 30 min. Tumor sections were incubated for 18 hours at 4°C in a humid chamber with the anti-beta-2 adrenergic receptor primary antibody (Santa Cruz Biotechnology, sc-9042, Santa Cruz, CA, USA) and diluted 1:50 in phosphate buffered saline (PBS) with bovine serum albumin solution (Sigma, A9647, St. Louis, MO, USA) to block nonspecific reactions. Next, the tumor sections were sequentially incubated with Post Primary Block (Novocastra, NovoLink Max Polymer, RE7260-K, Newcastle Upon Tyne, UK) for 30 min, followed by incubation with the Polymer from the same kit. The antigen-antibody reactions were revealed using 3,3′ diaminobenzidine tetrahydrochloride (DAB/Sigma, D-5637, St. Louis, MO, USA) for 5 min in the dark. Tumor sections were counterstained with Harris hematoxylin before being dehydrated and prepared with a cover slip. The vascular smooth muscle within the sections served as the positive internal control. For a negative control, the primary antibody was omitted during the immunohistochemical staining. All the OSCC specimens were immunostained in a single session.

Ten microscopic fields of the tumor-free margins were captured using 400x magnification to analyze the immunohistochemical expression of β2-AR. Images were obtained digitally with a camera (Axiocam MRC, ZEISS, Jena, Germany) attached to a light microscope ( Axioskop 2 Plus, ZEISS, Jena, Germany) and saved in a computer program system (Axiovision 4.6, ZEISS, Jena, Germany). The immunohistochemical expression of β2-AR was evaluated as previously described [21]. Briefly, the ImageJ software
AR expression pattern was conducted through immunohistochemical analysis of the 62 OSCC specimens. Variations in the brown intensity of the malignant cells positive for β2-AR expression were categorized according to the following RGB channel value ranges:

- R (red) channel was from 90 to 194;
- G (green) channel was from 50 to 140;
- B (blue) channel was from 45 to 147;
- the R value should be greater than the B value;
- the G value should be greater than the B value.

Ten images captured from the surgical margins of each OSCC were automatically segmented using the MATLAB computing language-based software according to the criteria listed above. This software measures, based on the number of pixels, each segmented area (determining the β2-AR immunopositive regions). After performing this computer-assisted immunohistochemistry analysis, the average of the β2-AR expression levels in ten surgical margin images was calculated. Next, the averages of 62 OSCC specimens, previously obtained by Bravo-Calderón et al. [21], were placed in ascending order and the median was established as the cut-off point to classify the specimens as exhibiting weak/negative (averages 0.62 to 23.86) or strong (averages 25.99 to 79.63) β2-AR expression. This measurement of β2-AR expression by epithelial cells of surgical margins was then subjectively confirmed by three investigators (Denise Tostes Oliveira, Gustavo Amaral Lauand, and Diego Mauricio Bravo-Calderón) without knowledge of the histopathological features and patient clinical status. In case of discordance between these analyzers, the criterion of the subjective evaluation was retained because this assessment involved the entire specimen.

In addition, knowing that most antigens are influenced adversely by formalin fixation [28], a confirmation of β2-AR expression pattern was conducted through immunohistochemical staining of 19 additional frozen sections of OSCC obtained from the Anatomical Pathology Service, Clinical Hospital University of Santiago, Santiago de Compostela, Spain.

2.3. Statistical Analysis. All statistical analysis was performed using the SPSS 13.0 for Windows software (SPSS Inc., Chicago, IL, USA). Correlation between β2-AR expressions in the tumor-free surgical margins and at the invasive front of OSCCs was verified by Pearson’s correlation coefficient test. The association between the β2-AR expression and clinical-pathological variables was analyzed by the chi-square or Fisher’s exact tests. For all tests, \( p \leq 0.05 \) was considered to represent a statistically significant result.

3. Results

Immunohistochemical analysis of the 62 OSCC specimens revealed a positive expression of β2-AR in parakeratinized stratified squamous epithelium of all tumor-free surgical margins, and 50 (80.6%) demonstrated strong expression of β2-AR levels. β2-AR immunostaining was detected at the cytoplasm and at the plasma membrane of normal epithelial cells in tumor-free surgical margins. Similarly, the same pattern of β2-AR expression (cytoplasmic and membranous) was identified in malignant epithelial cells at the invasive front of tumors.

Interestingly, Pearson’s correlation coefficient test detected a statistically significant and positive correlation between the β2-AR expression levels in tumor-free surgical margins and at the invasive front of tumors (\( r = 0.383; p = 0.002 \)) (Figure 1). Effectively, most (64.5%) of the 62 OSCC specimens had an increase of β2-AR expression levels in the tumor-free surgical margins, and it was accompanied by an increase of the expression levels at the invasive front. In other words, those specimens with weak β2-AR expression in the tumor-free surgical margin also exhibited weak/negative immunostaining of this protein in their respective invasive tumor front; and similarly, when the immunostaining of β2-AR was strong in normal oral epithelial cells, at the tumor-free surgical margin, the expression levels of this protein in malignant epithelial cells at the invasive front of the tumor were also high (Figure 1).

On the other hand, 22 (35.5%) OSCC samples presented no correlation between β2-AR levels in the tumor-free surgical margins and at the invasive front of tumors, as shown in Figure 1. In 20 of these noncorrelated cases (32.25% of the total sample), the invasive front of tumor presented a decrease of β2-AR expression levels when compared to their respective tumor-free surgical margins (Figure 1). On the other hand, the pattern of β2-AR expression found in the tumor-free surgical margin and at the invasive tumor front of OSCC is illustrated in Figure 2.

An additional analysis was performed to confirm our findings in formalin-fixed, paraffin-embedded tissue material.
by the evaluation of 19 new OSCC frozen specimens, β2-AR expression, in this sample, was verified in most OSCC specimens, being positively immunoexpressed in 87.5% of the tumor-free surgical margins and in 55.5% of the front of invasion. In the basal and corneum layers of the surgical margins or in the keratin pearls of oral cancers, no immunoexpression of β2-AR was detected. Furthermore, the cytoplasmic and membranous expressions of β2-AR were confirmed in oral epithelial cells adjacent to the tumor, as well as in the malignant epithelial cells of OSCC.

3.1. Associations between β2-AR Expression and Clinicopathological Variables. To determine the possible clinical significance of β2-AR expression in oral cancer and the associations between this protein expression and the clinicopathological features of OSCC patients, chi-square or Fischer’s exact tests were performed.

No statistically significant associations were found regarding immunohistochemical expression of β2-AR in the tumor-free surgical margins and clinical variables evaluated (Table 1). On the other hand, β2-AR immunoexpression at the
Table 1: Association between clinical parameters and β2-AR expression in 62 patients with oral squamous cell carcinoma.

| Variable          | Beta-2 adrenergic receptor | Invasive tumor front |
|-------------------|----------------------------|----------------------|
|                   | Weak (N = 12) | Moderate/strong (N = 50) | N (%) | N (%) | P | Weak/negative (N = 36) | Moderate/strong (N = 26) | P  |
| Gender            | Male | 8 (66.7) | 44 (88) | 0.091 | 31 (86.1) | 21 (80.8) | 0.729 |
|                   | Female | 4 (33.3) | 6 (12) | 0.091 | 5 (13.9) | 5 (19.2) | 0.729 |
| Ethnic group      | White | 10 (83.3) | 45 (90) | 0.612 | 33 (91.7) | 22 (84.6) | 0.439 |
|                   | Not white | 2 (16.7) | 5 (10) | 0.612 | 3 (8.3) | 4 (15.4) | 0.439 |
| Age               | ≤58 years | 8 (66.7) | 25 (50) | 0.299 | 22 (61.1) | 11 (42.3) | 0.143 |
|                   | >58 years | 4 (33.3) | 25 (50) | 0.299 | 14 (38.9) | 15 (57.7) | 0.143 |
| Tobacco           | Yes | 11 (100) | 42 (93.3) | 0.999 | 31 (100) | 22 (88) | 0.083 |
|                   | No | 0 (0) | 3 (6.7) | 0.999 | 0 (0) | 3 (12) | 0.083 |
| Alcohol           | Yes | 10 (90.9) | 32 (69.6) | 0.256 | 27 (84.4) | 15 (60) | 0.038* |
|                   | No | 1 (9.1) | 14 (30.4) | 0.256 | 5 (15.6) | 10 (40) | 0.038* |
| Tobacco + alcohol | Yes | 10 (90.9) | 29 (64.4) | 0.144 | 26 (83.9) | 13 (52) | 0.010* |
|                   | No | 1 (9.1) | 16 (35.6) | 0.144 | 5 (16.1) | 12 (48) | 0.010* |
| T stage           | T1/T2 | 6 (50) | 28 (56) | 0.708 | 15 (41.7) | 19 (73.1) | 0.014* |
|                   | T3/T4 | 6 (50) | 22 (44) | 0.708 | 21 (58.3) | 7 (26.9) | 0.014* |
| N stage           | N+ | 6 (50) | 24 (48) | 0.901 | 18 (50) | 12 (46.2) | 0.765 |
|                   | N0 | 6 (50) | 26 (52) | 0.901 | 18 (50) | 14 (53.8) | 0.765 |
| Clinical stage    | II | 3 (25) | 16 (32) | 0.74 | 9 (25) | 10 (38.5) | 0.257 |
|                   | III/IV | 9 (75) | 34 (68) | 0.74 | 27 (75) | 16 (61.5) | 0.257 |
| Recurrence        | Yes | 6 (50) | 20 (40) | 0.528 | 17 (47.2) | 9 (34.6) | 0.321 |
|                   | No | 6 (50) | 30 (60) | 0.528 | 19 (52.8) | 17 (65.4) | 0.321 |
| Metastases        | Yes | 0 (0) | 1 (2) | 0.999 | 0 (0) | 1 (3.8) | 0.419 |
|                   | No | 12 (100) | 49 (98) | 0.999 | 36 (100) | 25 (96.2) | 0.419 |
| Second primary tumor | Yes | 1 (8.3) | 8 (16) | 0.675 | 5 (13.9) | 4 (15.4) | 0.999 |
|                   | No | 11 (91.7) | 42 (84) | 0.675 | 31 (86.1) | 22 (84.6) | 0.999 |

N: number of cases; p: p value obtained by chi-square test or Fisher’s exact test; #excluding patients with lost records; **local and/or regional recurrence; * statistically significant result.

invasive tumor front was statistically associated with alcohol consumption (p = 0.038), simultaneous consumption of alcohol, and tobacco (p = 0.010) and with the clinical T stage (p = 0.014), as shown in Table 1. Most OSCC patients with weak/negative expression of β2-AR at the invasive front of tumor exhibited alcohol consumption or alcohol and tobacco consumption. In addition, strong β2-AR expression by malignant epithelial cells was more frequently detected in patients with early clinical stage of T1/T2.

Regardless of the area that was considered for analysis, either the tumor-free surgical margin or the invasive tumor front, no statistically significant association between β2-AR expression and the histopathological characteristics was shown, including grade of malignancy, lymph nodes involvement (pN+), vascular embolization and perineural invasion, and muscular or bone infiltration (Table 2).

4. Discussion

Although several studies have described the functional localization of β2-AR in a wide variety of cells including those of the tumor microenvironment, the expression pattern of this receptor in normal oral epithelium and in malignant epithelial cells is not well defined yet [1–3, 6, 8–24]. Our immunohistochemical analysis of a large cohort of OSCC specimens has shown a cytomembranous expression of β2-AR in normal oral epithelial cells of all tumor-free surgical margins, except for the corneum and basal layers (Figure 2). These findings corroborate previous reports that identified β2-AR as the main adrenergic receptor subtype in cultured human oral keratinocytes and those in which a RT-PCR assay verified the expression of β2-AR mRNA in 14 of 15 specimens of normal oral mucosa [3, 18]. Collectively, data obtained by
AR mRNA expression in not matched specimens of normal us and by mentioned reports [3, 18] suggest that $\beta_2$-AR is constitutively expressed in normal oral epithelium.

Concerning OSCC, similarly to normal epithelium, the invasive front of tumor is considered as the most progressed region by Piffk`oe et al. [29], and approximately three to six tumor cell layers or detached tumor cell groups were positively immunostained for $\beta_2$-AR at the cytoplasm and plasma membranes of malignant epithelial cells, except for the keratin pearls that were negative (Figure 2). In addition, the present study is the first to demonstrate that the expression of $\beta_2$-AR in surgical margins is positively correlated with the invasive front of tumor expression levels ($r = 0.383; p = 0.002$) (Figure 1). Despite methodological differences, our findings corroborate the observations proposed by Bernab´e et al. [18] which reported no expressive difference in $\beta_2$-AR expression by malignant tumors [1, 2, 6–25]. However, the effects of stress related hormones can be stimulatory or inhibitory, depending on the type of hormone and the tumor type [25]. In this context, the role of $\beta_2$-AR in the progression of oral cancer is not well established. Thus, the scientific literature has demonstrated that $\beta_2$-AR immunoexpression by malignant cells is significantly correlated with age, tumor size, clinical stage, and cervical lymph node metastasis in OSCC patients [16]. Nevertheless, the present clinical study revealed that patients clinically classified as T3 or T4 exhibited a higher frequency of weak/negative $\beta_2$-AR expression at the invasive tumor front (Table 1). In addition, considering that $\beta_2$-AR was presented in all tumor-free surgical margins, it was expected that no statistically significant associations would be found regarding immunohistochemical expression in the normal oral epithelial cells and clinicopathological variables evaluated (Tables 1 and 2).

On the other hand, the evidence that, in certain OSCCs, $\beta_2$-AR expression by tumoral cells may decrease (Figure 1), as previously shown in patients with oral cancer and weak/negative $\beta_2$-AR expression and low survival rates, compared with strong $\beta_2$-AR expression [21], reinforces previous findings obtained by Yu et al. [10]. Yu et al. demonstrated that genetic silencing of $\beta_2$-AR increases cell migration and invasion in normal prostate cells and that weak expression of this protein was associated with metastases and worst survival rates in prostate cancer patients. Considering the present results, other studies with $\beta_2$-AR expression should be performed to further elucidate the role of this receptor. In vitro analyses are suggested with the stimulatory and inhibitory factors for $\beta_2$-AR.

### Table 2: Association between histopathological parameters and $\beta_2$-AR expression in 62 patients with oral squamous cell carcinoma.

| Variable                              | Beta-2 adrenergic receptor | Tumor-free margin | Invasive tumor front |
|---------------------------------------|----------------------------|------------------|---------------------|
|                                       | Weak (N = 12) | Moderate/strong (N = 50) | P | Weak/negative (N = 36) | Moderate/strong (N = 26) | P |
| Malignancy grading                    |               |                   |               |               |               |               |
| M. diff.                              | 10 (83.3)    | 44 (88)           | 0.645         | 31 (86.1)    | 23 (88.5)    | 0.999         |
| L. diff.                              | 2 (16.7)     | 6 (12)            |               | 5 (13.9)     | 3 (11.5)     |               |
| Vascular embolization                 |               |                   |               |               |               |               |
| Yes                                   | 9 (75)       | 26 (52)           | 0.149         | 23 (63.9)    | 12 (46.2)    | 0.165         |
| No                                    | 3 (25)       | 24 (48)           |               | 13 (36.1)    | 14 (53.8)    |               |
| Perineural infiltration               |               |                   |               |               |               |               |
| Yes                                   | 9 (75)       | 36 (72)           | 0.999         | 24 (66.7)    | 21 (80.8)    | 0.219         |
| No                                    | 3 (25)       | 14 (28)           |               | 12 (33.3)    | 5 (19.2)     |               |
| Muscular infiltration                 |               |                   |               |               |               |               |
| Yes                                   | 11 (91.7)    | 43 (86)           | 0.999         | 31 (86.1)    | 23 (88.5)    | 0.999         |
| No                                    | 1 (8.3)      | 7 (14)            |               | 5 (13.9)     | 3 (11.5)     |               |
| Bone infiltration f                    |               |                   |               |               |               |               |
| Yes                                   | 1 (8.3)      | 5 (10.2)          | 0.999         | 5 (14.3)     | 1 (3.8)      | 0.227         |
| No                                    | 11 (91.7)    | 44 (89.8)         |               | 30 (85.7)    | 25 (96.2)    |               |
| Lymph node involvement                | pN+           |                   |               | 18 (50)      | 12 (46.2)    | 0.765         |
|                                       | pN0           |                   |               | 18 (50)      | 14 (53.8)    |               |

$N$: number of cases; $p$: value obtained by chi-square test or Fisher’s exact test; M. diff.: more differentiated tumor; L. diff.: less differentiated tumor; f excluding patients with lost records.
5. Conclusions

Thereby, in light of these results we can conclude that although the present study reinforces that β2-AR is constitutive in normal oral epithelial cells and is positively correlated with the expression levels of β2-AR by OSCC cells, further clinical, cellular, and animal studies are needed to elucidate the role of β2-AR in oral cancer, specially, in relation to the importance of its decrease on tumor progression.

Abbreviations

β2-AR: Beta-2 adrenergic receptor
OSCC: Oral squamous cell carcinoma.

Ethical Approval

The present study was approved by the Research Ethics Committee of the A.C. Camargo Cancer Center, São Paulo, Brazil (#1385/10).

Competing Interests

The authors report they have no conflict of interests.

Acknowledgments

The authors would like to thank the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Grants #2011/11630-0 and #2012/04098-2) and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Grants #142790/2011-7 and #142175/2015-3) for supporting the present study.

References

[1] P. H. Thaker, L. Y. Han, A. A. Kamat et al., “Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma,” Nature Medicine, vol. 12, no. 8, pp. 939–944, 2006.
[2] E. V. Yang, A. K. Sood, M. Chen et al., “Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells,” Cancer Research, vol. 66, no. 21, pp. 10357–10364, 2006.
[3] P. Steenhuis, R. E. Huntley, Z. Gurenko et al., “Adrenergic signaling in human oral keratinocytes and wound repair,” Journal of Dental Research, vol. 90, no. 2, pp. 186–192, 2011.
[4] M. Pérez-Sayáns, J. Somoza-Martín, F. Barros-Angueira et al., “Activity of β2-adrenergic receptor in oral squamous cell carcinoma is mediated by overexpression of the ADRBK2 gene: a pilot study,” Biotechnic and Histochemistry, vol. 87, no. 3, pp. 179–186, 2012.
[5] Y. Daaka, L. M. Luttrell, and R. J. Lefkowitz, “Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A,” Nature, vol. 390, no. 6655, pp. 88–91, 1997.
[6] K. Masur, B. Niggemann, K. S. Zanker, and F. Entschladen, “Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by β-blockers,” Cancer Research, vol. 61, no. 7, pp. 2866–2869, 2001.
[7] M. H. Antoni, S. K. Lutgendorf, S. W. Cole et al., “The influence of bio-behavioural factors on tumour biology: pathways and mechanisms,” Nature Reviews Cancer, vol. 6, no. 3, pp. 240–248, 2006.
[8] D. Palm, K. Lang, B. Niggemann et al., “The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by β-blockers,” International Journal of Cancer, vol. 118, no. 11, pp. 2744–2749, 2006.
[9] K. S. R. Sastry, Y. Karpova, S. Prokopovich et al., “Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation,” The Journal of Biological Chemistry, vol. 282, no. 19, pp. 14094–14100, 2007.
[10] J. Yu, Q. Cao, R. Mehra et al., “Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer,” Cancer Cell, vol. 12, no. 5, pp. 419–431, 2007.
[11] X. Liu, W. K. K. Wu, L. Yu et al., “Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via β-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway,” Journal of Cellular Biochemistry, vol. 105, no. 1, pp. 53–60, 2008.
[12] X. Liu, W. K. K. Wu, L. Yu et al., “Epidermal growth factor-induced esophageal cancer cell proliferation requires transactivation of β-adrenoceptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 1, pp. 69–75, 2008.
[13] E. V. Yang, S.-J. Kim, E. L. Donovan et al., “Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression,” Brain, Behavior, and Immunity, vol. 23, no. 2, pp. 267–275, 2009.
[14] P. Bastian, A. Balcarek, C. Altanis et al., “The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway,” Cancer Letters, vol. 274, no. 2, pp. 218–224, 2009.
[15] K. Guo, Q. Ma, L. Wang et al., “Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol,” Oncology Reports, vol. 22, no. 4, pp. 825–830, 2009.
[16] Z. J. Shang, K. Liu, and D. F. Liang, “Expression of β2-adrenergic receptor in oral squamous cell carcinoma,” Journal of Oral Pathology and Medicine, vol. 38, no. 4, pp. 371–376, 2009.
[17] D. Zhang, Q. Ma, S. Shen, and H. Hu, “Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of β-adrenoceptor antagonist’s anticancer effect in pancreatic cancer cell,” Pancreas, vol. 38, no. 1, pp. 94–100, 2009.
[18] D. G. Bernabé, A. C. Tamae, É. R. Biasoli, and S. H. P. Oliveira, “Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells,” Brain, Behavior, and Immunity, vol. 25, no. 3, pp. 574–583, 2011.
[19] S. Y. Park, J. H. Kang, K. J. Jeong et al., “Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism,” International Journal of Cancer, vol. 128, no. 10, pp. 2306–2316, 2011.
[20] P. Zhang, X. He, J. Tan, X. Zhou, and L. Zou, “β-Arrestin2 mediates β-2 adrenergic receptor signaling inducing prostate cancer cell progression,” Oncology Reports, vol. 26, no. 6, pp. 1471–1477, 2011.
[21] D. M. Bravo-Calderón, D. T. Oliveira, A. N. Marana, S. Nonogaki, A. L. Carvalho, and L. P. Kowalski, “Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma,” Cancer Biomarkers, vol. 10, no. 1, pp. 51–59, 2012.
[22] T. Shan, J. Ma, Q. Ma et al., “β2-AR-HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis,” *Current Molecular Medicine*, vol. 13, no. 6, pp. 1023–1034, 2013.

[23] A.-M. Stock, D. G. Powe, S. A. Hahn et al., “Norepinephrine inhibits the migratory activity of pancreatic cancer cells,” *Experimental Cell Research*, vol. 319, no. 12, pp. 1744–1758, 2013.

[24] R. Yang, Q. Lin, H. B. Gao, and P. Zhang, “Stress-related hormone norepinephrine induces interleukin-6 expression in GES-1 cells,” *Brazilian Journal of Medical and Biological Research*, vol. 47, no. 2, pp. 101–109, 2014.

[25] P. H. Thaker, S. K. Lutgendorf, and A. K. Sood, “The neuroendocrine impact of chronic stress on cancer,” *Cell Cycle*, vol. 6, no. 4, pp. 430–433, 2007.

[26] L. H. Sobin and C. Wittekind, *TNM: Classification of Malignant Tumors*, John Wiley & Sons, New York, NY, USA, 2002.

[27] M. Bryne, H. S. Koppang, R. Lilleng, T. Stene, G. Bang, and E. Dabelsteen, “New malignancy grading is a better prognostic indicator than Broders’ grading in oral squamous cell carcinomas,” *Journal of Oral Pathology and Medicine*, vol. 18, no. 8, pp. 432–437, 1989.

[28] S.-R. Shi, R. J. Cote, and C. R. Taylor, “Antigen retrieval immunohistochemistry: past, present, and future,” *Journal of Histochemistry and Cytochemistry*, vol. 45, no. 3, pp. 327–343, 1997.

[29] J. Piffkò, Á. Bánkfalvi, K. Tory et al., “Molecular assessment of p53 abnormalities at the invasive front of oral squamous cell carcinomas,” *Head and Neck*, vol. 20, no. 1, pp. 8–15, 1997.